Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Parving
H H
HH
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000517:prevention & control*; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D008148:Lovastatin / Q000627:therapeutic use*; D011507:Proteinuria; D012107:Research Design
D000924:Anticholesteremic Agents; D008148:Lovastatin